(Press-News.org) Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.
These types of medication -- GLP-1 receptor agonists -- are a newer class of FDA-approved therapeutics that are generally used in addition to metformin for control of blood sugar or to induce weight loss in patients with obesity.
Researchers from Vanderbilt University Medical Center, Brigham and Women's Hospital, Harvard Medical School and University Hospital Zurich in Switzerland used electronic health record (EHR) data of patients with asthma and type 2 diabetes who initiated treatment with GLP-1R agonists, finding lower rates of asthma exacerbations and reduced asthma symptoms as compared to those who initiated other type 2 diabetes medications.
Their findings were published in the American Journal of Respiratory and Critical Care Medicine.
"We have demonstrated really for the first time that this class of medications used to treat type 2 diabetes and obesity may also have benefit for our patients who have asthma," said lead author Katherine Cahill, MD, medical director of Clinical Asthma Research in the Division of Allergy, Pulmonary, and Critical Care Medicine at VUMC.
"In a six-month period, type 2 diabetes patients who received this form of medication to improve blood sugar control also had better control of their asthma disease and symptoms compared to those who took alternative therapies," she said.
Cahill's study was a retrospective, observational study, so definitive prospective studies such as a clinical trial in patients with asthma, with and without comorbid type 2 diabetes, are required to confirm these medications provide benefit for asthma.
"For patients who have type 2 diabetes and asthma it means that some of their medications for type 2 diabetes may actually help their asthma control," Cahill said.
"For patients who have asthma but may not have type 2 diabetes it means that there could be a new class of medications that could be used for treatment."
In preclinical models completed at VUMC, GLP-1R agonists have been shown to reduce allergic airway inflammation and viral-induced airway inflammation. To translate these findings into human disease, Cahill and colleagues took advantage of the widespread use of GLP-1R agonists for the treatment of type 2 diabetes and available clinical information in EHR data.
VUMC colleagues Shinji Toki, PhD, Melissa Bloodworth, MD, PhD, Stokes Peebles, MD, and Kevin Niswender, MD, PhD, had previously shown in preclinical models of asthma that this class of medications reduces inflammation in the lung as well as how the lung responds to certain challenges like allergies and viruses. Other early preclinical data also suggest it is possible this therapy could have benefits in the airway for other airway diseases.
"In our study we found that patients with asthma received benefits from this medication because they had improved asthma control, so fewer asthma symptoms, and fewer acute flares, or what we call exacerbations, of their asthma," Cahill said.
"Our study demonstrated that the patients reported better breathing symptoms and fewer reports of shortness of breath and cough."
One member of the class of medications that induces early satiety, leading to weight loss, is already approved for the treatment of obesity. Future studies will investigate if the drug could improve outcomes for patients with both asthma and obesity.
Cahill and VUMC colleagues have received National Institutes of Health (NIH) funding to initiate a randomized, controlled clinical trial of GLP-1R agonists in asthma during the next year.
"Our next step is to take this medication and study it in patients with asthma. Here at Vanderbilt, we are going to actually be looking at patients who are obese and have asthma and assess whether the drug actually makes their asthma better or not," Cahill said.
INFORMATION:
The research was supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number K23AI118804.
'Don't forget the mask' - although most people nowadays follow this advice, professionals express different opinions about the effectiveness of face masks. An international team led by researchers from the Max Planck Institute for Chemistry in Mainz, Germany, has now used observational data and model calculations to answer open questions. The study shows under which conditions and in which way masks actually reduce individual and population-average risks of being infected with COVID-19 and help mitigate the corona pandemic. In most environments and situations, ...
PHILADELPHIA--A five-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania (ACC) to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group with historically low representation in cancer research. The percentage of patients enrolled into a treatment clinical trial, for example, increased from 12 to 24 percent. A significant increase was also observed in non-therapeutic interventional and non-interventional trials.
The findings were published today in an abstract to be presented at the American Society of Clinical Oncology annual meeting on June 5. (Abstract #100). [ADD ...
New York, NY (May 21, 2021) --Women who were highly exposed to ultra-fine particles in air pollution during their pregnancy were more likely to have children who developed asthma, according to a study published in the American Journal of Respiratory and Critical Care Medicine in May. This is the first time asthma has been linked with prenatal exposure to this type of air pollution, which is named for its tiny size and which is not regulated or routinely monitored in the United States.
Slightly more than 18 percent of the children born to these mothers developed asthma in their preschool years, compared ...
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.
In the 18 months since the first report of COVID-19 and the spread of the pandemic, there has been a large amount of research into understanding it and developing menas to treat it. COVID-19 does not affect all infected individuals equally. Many individuals are asymptomatic; of those who are symptomatic, the large majority have mild symptoms, and only a small number have severe cases. The reasons for this are not fully understood and are an important area of ongoing research.
A team of scientists ...
The issue of concern was that the Escherichia coli (E. coli) genome, consisting of 4.6 million base pairs of a single circular DNA, is too large to manipulate following the extraction and transfer to other bacteria.
In the present study, a group of Rikkyo University researchers led by Assistant Professor Takahito Mukai and Professor Masayuki Su'etsugu has succeeded in splitting the E.coli genome into tripartite-genome of 1 million base pairs per genome (split-genome) using the smallest E. coli genome strain established so far. In addition, they successfully extracted the split-genome from bacteria and installed it in other E. ...
All living organisms are equipped with sensory organs to detect changes in their surrounding environment. It may not immediately strike us as obvious but, similar to how we can sense heat, cold, light, and darkness, we are also extremely adept at sensing gravity. In our case, it is our inner ear that does this job, helping us maintain balance, posture, and orientation in space. But, what about other organisms, for instance invertebrates that lack a backbone?
The gravity sensing organ in some aquatic invertebrates, known as a "statocyst," is, in fact, rather fascinating. The statocyst is essentially a fluid-filled sac with sensory cells lining its inner wall and a small, mineralized ...
[Highlights]
- Integrated cyber attack analysis platform "NIRVANA Kai" newly supports IPv6 and enhances its functions.
- Observation of IPv6 communications, collection of IPv6-related alerts, and real-time visualization of IPv6 networks.
- Expected to simplify security operations in IPv6 networks.
[Abstract]
The Cybersecurity Laboratory of the National Institute of Information and Communications Technology (NICT, President: TOKUDA Hideyuki, Ph.D.) has enhanced its cyber attack integrated analysis platform "NIRVANA Kai" to support the Internet Protocol version ...
China's clean air policies have substantially reduced PM2.5 air pollution in recent years. Yet >99% of Chinese population is still exposed to PM2.5 concentrations in excess of the World Health Organization (WHO) Air Quality Guidelines of 10 μg/m3. Climate actions targeting to reduce fossil fuel consumption also have substantial air quality benefits. The announcement of ambitious climate commitment to achieve carbon neutrality by 2060 may fuel the power to long-term air quality improvement in China.
Combining Global/China's climate mitigation pathways (i.e. global 2°C- and 1.5°C-pathways, NDC pledges, and carbon neutrality goals) and local clean ...
An international research group involving the Institute of Molecular and Cellular Biology of Plants (IBMCP), a joint centre of the Universitat Politècnica de València (UPV) and the Spanish National Research Council (CSIC), has discovered that a genetic mechanism, called CHLORAD, which is involved in the ageing of plant leaves, also plays a decisive role in the tomato ripening process. Thus, tomatoes with an activated CHLORAD system turn red more quickly, and accumulate more lycopene, a compound beneficial to health. The results, which have been published in the latest issue of the journal Nature Plants, will lead to better quality tomatoes.
The ripening of most fleshy fruits gives them attractive colours and smells, which is a trick of the plant to spread its seeds ...
Most of commercial chemicals are produced using catalysts. Usually, these catalysts consist of tiny metal nanoparticles that are placed on an oxidic support. Similar to a cut diamond, whose surface consists of different facets oriented in different directions, a catalytic nanoparticle also possesses crystallographically different facets - and these facets can have different chemical properties.
Until now, these differences have often remained unconsidered in catalysis research because it is very difficult to simultaneously obtain information about the chemical reaction itself and about the surface structure of the catalyst. At TU Wien (Vienna), this has now been achieved by combining different microscopic methods: with ...
